<div id="readability-page-1"><p>Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $197.06, but opened at $202.20. Charles River Laboratories International shares last traded at $201.77, with a volume of 2,396 shares traded.</p><h2>Analysts Set New Price Targets</h2><ul><li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li></ul><p>Several brokerages have recently issued reports on CRL. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $200.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday, October 3rd. William Blair raised shares of Charles River Laboratories International from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research note on Monday, October 6th. TD Cowen lowered their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 10th. Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Charles River Laboratories International from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Sunday. One equities research analyst  has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $195.93.</p><p><b>Get Our Latest Stock Analysis on Charles River Laboratories International</b></p><h2>Charles River Laboratories International Trading Down 0.1%</h2><p>The stock has a market capitalization of $9.99 billion, a price-to-earnings ratio of -129.82, a PEG ratio of 6.96 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The business's 50-day simple moving average is $180.48 and its two-hundred day simple moving average is $166.13. </p><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the previous year, the business posted $2.59 EPS. The business's quarterly revenue was down .5% on a year-over-year basis.  On average, research analysts anticipate that  Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Charles River Laboratories International</h2><p>A number of institutional investors have recently added to or reduced their stakes in CRL. American Century Companies Inc. increased its stake in shares of  Charles River Laboratories International by 29.1% in the first quarter. American Century Companies Inc. now owns 3,853 shares of the medical research company's stock worth $580,000 after buying an additional 869 shares during the last quarter.  Brooklyn Investment Group raised its stake in shares of  Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after purchasing an additional 86 shares in the last quarter.  Hsbc Holdings PLC lifted its position in shares of  Charles River Laboratories International by 2.0% during the first quarter. Hsbc Holdings PLC now owns 81,813 shares of the medical research company's stock worth $12,270,000 after purchasing an additional 1,611 shares during the last quarter.  Norinchukin Bank The increased its holdings in shares of  Charles River Laboratories International by 13.3% in the 1st quarter. Norinchukin Bank The now owns 2,554 shares of the medical research company's stock valued at $384,000 after acquiring an additional 299 shares during the last quarter.  Finally, Ameriprise Financial Inc. raised its position in shares of  Charles River Laboratories International by 144.3% during the 1st quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company's stock valued at $82,007,000 after acquiring an additional 321,789 shares in the last quarter. Institutional investors and hedge funds own  98.91% of the company's stock. </p><h2>About Charles River Laboratories International</h2> (Get Free Report)<p>Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.  </p><p>Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Charles River Laboratories International</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p><p>While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Charles River Laboratories International's stock opened higher at $202.20 from a previous close of $197.06. Analysts have adjusted their ratings, with Evercore ISI and William Blair giving an "outperform" rating, while TD Cowen set a "buy" rating despite lowering the price target. The stock has a "Moderate Buy" consensus with an average price target of $195.93. The company reported better-than-expected earnings per share of $2.43 for the recent quarter.</p>

Charles River Laboratories International (NYSE:CRL) Shares Gap Up - Here's What Happened